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This study aimed to determine the survival outcome and prognostic factors of patients with
nasopharyngeal cancer accessing treatment in Yogyakarta, Indonesia.
Methods
Data on 759 patients with NPC diagnosed from 2007 to 2016 at Dr Sardjito General Hospital
were included. Potential prognostic variables included sociodemographic, clinicopathology
and treatment parameters. Multivariable analyses were implemented using semi-parametric
Cox proportional hazards modelling and fully parametric survival analysis.
Results
The median time of observation was 14.39 months. In the whole cohort the median
observed survival was 31.08 months. In the univariable analysis, age, education status,
insurance type, BMI, ECOG index, stage and treatment strategy had an impact on overall
survival (OS) (p values <0.01). Semi-parametric multivariable analyses with stage stratifica-
tion showed that education status, ECOG index, and treatment modality were independent
prognostic factors for OS (p values <0.05). In the fully parametric models age, education
status, ECOG index, stage, and treatment modality were independent prognostic factors for
OS (p values <0.05). For both multivariable analyses, all treatment strategies were
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associated with a reduced hazard (semi-parametric models, p values <0.05) and a better
OS (parametric models, p values <0.05) compared with no treatment. Furthermore, com-
pared with radiation alone or chemotherapy alone, a combination of chemotherapy and radi-
ation either in a form of concurrent chemoradiotherapy (CCRT), sequential chemotherapy
and radiation, or induction chemotherapy followed by CCRT demonstrated a reduced haz-
ard (hazard ratio/HR 0.226, 95% confidence interval/CI 0.089–0.363, and HR 0.390, 95%CI
0.260–0.519) and a better OS (time ratio/TR 3.108, 95%CI 1.274–4.942 and TR 2.531, 95%
CI 1.829–3.233) (p values < 0.01).
Conclusions
Median OS for the cohort was low compared to those reported in both endemic and non-
endemic regions. By combining the findings of multivariable analyses, we showed that age,
education status, ECOG index, stage and first treatment modality were independent predic-
tors for the OS.
Introduction
Nasopharyngeal cancer (NPC) is a relatively uncommon malignancy associated with tobacco
and alcohol use, and Epstein-Barr virus infection [1]. Worldwide, its annual incidence is 2.2/
100,000 persons in males and 0.8/100,000 persons in females [2]. However, it is a major health
problem in geographic areas including Southern China, Hong Kong, and South-East Asia [3–
5]. In Indonesia, NPC is the third most prevalent cancer in males with age-standardized
annual incidence rate of 10.5/100,000 males [6]. This rate is much higher than in Caucasian
populations (0.5/100,000 per year in males) [7].
The Tumour, Node, Metastasis (TNM) classification system includes six groups of NPC
based on tumor extension (T1-4), the involving nodals (N1-3), and the presence of metastasis
(M0-1) [8]. Stages I-II are considered as early disease and stage III, IVA, and IVB as locoregio-
nal advance disease and Stage IVC as distant metastasis.
Radiotherapy remains the standard care for NPC treatment, either alone or in combination
with chemotherapy [3, 4]. Radiation alone is generally applied in stage I disease. For stages
II-IVB, guidelines recommend concurrent chemoradiotherapy (CCRT) with adjuvant chemo-
therapy (AC) (CCRT-AC), induction chemotherapy (IC) followed by CCRT (IC-CCRT), or
CCRT alone [9, 10]. Combination chemotherapy and radiation treatment can also be applied
sequentially [11, 12]. For stage IVC, platinum-based chemotherapy is the preferred strategy for
chemonaive individuals with good performance [13], although chemoradiotherapy for locore-
gional disease can also be given [14].
Several studies have characterized differences in NPC survival in endemic areas. A higher
probability for poor overall survival (OS) in more advanced stages has been reported in both
endemic [15, 16] and non-endemic regions [17]. Histologically, risk of mortality is higher for
WHO type I when compared to WHO types II and III [18], although other studies report con-
tradictive findings [17]. A report from China in locally advanced cases treated with either
CCRT or IC-CCRT showed a 5-year overall survival (OS) of 74.8% and 83.2%, respectively
[19]. A study in Hong Kong demonstrated 5-year OS of 69.8% in patients diagnosed from
1976–2005. In Malaysia a 3-year OS rate was found at 94.3% for stage II, 80% for stage III and
79.8% for stage IV. The 3-year disease-free survival (DFS) rate was 90% for stage II, 80% for
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stage III and 65% for stage IV [12]. Observations from non-endemic areas include a study in
Slovenia that demonstrated a 5-year DFS of 59% and OS of 49.7% [20]. A Finnish study
reported a cohort diagnosed between 1990 and 2009. This showed a 5-year OS of 57%, with
OS for stages I-IV as 87%, 69%, 55% and 31%, respectively [17].
Beside disease stage, multiple factors such as sex and age have been identified to influence
OS. Relative risk of death is lower for female and younger cases compared to male and older
cases [4, 18, 19, 21], although some studies suggest younger age is associated with poorer DFS
[22]. Studies also report education (duration >12 years), marital status (being married,
divorced, or single, rather than widowed) and economic status (higher) as pre-treatment pre-
dictors of increased survival [10, 23, 24]. Furthermore, reports from the United States demon-
strated that individuals with uninsured cases (where insurance can be considered an indicator
of economic status) have a lower survival compared with cases possessing private insurance
[25, 26].
A trend of mortality rate by date of diagnosis of NPC has been demonstrated in the research
literature. An epidemiological study for the period 1980–1999 from the Hong Kong Cancer
Registry outlined a steadily decreasing age-standardized incidence rate from 28.5 in 1980–84
to 20.2 in 1995–99 per 100,000 males, and from 11.2 to 7.8 per 100,000 females, resulting in a
total decrease of 29% and 30%, respectively, over the 20-year period [27]. This was supported
by more recent studies in other endemic areas [18, 28]. A study in Finland also demonstrated
OS of patients treated in 1990–1999 at 49% and an OS of 63% for those treated in 2000–2009
[17].
The effect of pre-treatment nutritional status on survival of NPC patients remains contra-
dictory. A study in China showed that underweight increased the risk of death and distant
metastasis [29], whilst a study from Taiwan found no relationship between body mass index
(BMI), weight loss and survival [30]. In regards to general performance, a Chinese study in
patients with metachronous metastatic disease showed that Karnofsky performance index of
<80 had a negative impact on the survival [31].
The variation of treatment modality may have an effect on survival. Globally, capabilities of
radiotherapy technologies vary among centres, ranging from crude two-dimensional (2D)
radiotherapy techniques to more sophisticated modalities, such as intensity-modulated radia-
tion therapy (IMRT) [32]. Guidelines currently recommend IMRT as the preferred option [9,
10, 33]. A previous review of 1,593 consecutive cases treated with 2D radiotherapy, 3D radio-
therapy and IMRT highlighted differing rates of 5-year DFS at 78%, 81% and 85%, respectively.
The related 5-year OS of each modality was 71%, 73% and 80% [34]. A study in Malaysia
assessed the long-term survival of 91 locally advanced NPC patients who were treated with
conventional radical RT followed by adjuvant chemotherapy. The 5-year OS, DFS and loco-
regional control rate was 80.1%, 76%, and 85%, respectively [12]. A study of 602 cases with
stage IVA-B NPC treated with IMRT showed that the 5-year OS was 83.2% for IC-CCRT and
74.8% for CCRT alone [19]. Metastatic NPC cases are generally treated with palliative chemo-
therapy or added with radiation on loco-regional disease, with median survival ranges from
9.5–15 months [13, 14, 35].
Although NPC is highly prevalent in Indonesia, there is no comprehensive report on
patients’ survival with factors affecting survival not well understood or widely reported. The
largest dataset to have been reported from Indonesia included an analysis of clinical and path-
ological features only [36, 37]. Indeed, there are few reports of survival analyses of NPC in
Indonesia. The present study aims to address this gap in the literature by presenting a survival
analysis of a patient population attending a teaching hospital in Yogyakarta, Indonesia, and
explores prognostic parameters that have been reported in the literature. This work seeks to
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develop the evidence base on factors that influence survival for NPC cases in Indonesia to
guide the development of a suitable response in the provision of cancer care.
Methods
Study population
An NPC clinical registry was developed in 2012 at Dr Sardjito General Hospital Yogyakarta
Indonesia. The registry includes data on all patients diagnosed and treated at the hospital from
January 2007 to December 2016. Data were collected and collated from 2012 till 2018 and
extracted from medical records and paired with data from the pathological department. Writ-
ten informed consent was obtained from participants prior to medical treatment. This retro-
spective study that utilised data from the registry was approved by the Joint Ethics Committee
of Faculty of Medicine, Public Health, and Nursing at Universitas Gadjah Mada and Dr Sard-
jito General Hospital (reference number: KE/FK/0250/EC/2018).
Details concerning patient characteristics, presentation of the disease, treatment and fol-
low-up were obtained from medical records. The histological diagnosis was made according to
the WHO classification of NPC [38]. Pre-treatment evaluations included gathering of sociode-
mographic characteristics (sex, age, educational status, marital status and insurance type), year
of diagnosis, BMI, performance status (by the Eastern Cooperative Oncology Group/ECOG
classification), a chest X-ray, computed tomography (CT) of the head-and-neck region, an
abdominal ultrasound and a bone X-ray. CT scans of the abdominopelvic region or chest were
conducted when clinically indicated. Patients underwent clinical staging according to the
American Joint Committee on Cancer staging system. Staging was aligned with the 6th edition
for diagnoses made prior to 2010 [39], and those from 2010 aligned with the 7th edition [8].
Staging was harmonised across levels of the 7th edition for the analysis.
Treatment and follow-up
Treatment data was obtained from the clinical registry and ambulatory clinic charts. Generally,
for adjuvant treatment intention, a conventional fractionated schedule of radiation (daily frac-
tion of 2 Gy with a total 33–35 fractions) was given. In 2007–2016 2D and 3D conventional
radiotherapy techniques were used. Early in 2017, application of IMRT was applied. Different
strategies of chemotherapy for locally advanced disease were given due to the waiting time to
radiation which included sequential chemotherapy and radiotherapy, CCRT alone, or
IC-CCRT. For cases who had been planned to have sequential treatment or IC-CCRT, the TPF
regimen (comprising of intravenous docetaxel 75 mg/m2 on day 1, cisplatin 100 mg/m2 on
day 1 and 5-fluoro-uracil 1000 mg/m2/day on day 1–4, every 3 weeks) was applied. Alterna-
tively, PF regimen (comprising of intravenous cisplatin 100 mg/m2/day on day 1 and 5-fluoro-
uracil 1000 mg/m2/day on day 1–5, every 3 weeks) was applied for a 3–4 courses. In cases that
needed to wait for long periods to begin a radiation schedule, chemotherapy courses with PF
regimen were extended depending on the clinical conditions. In the CCRT scheme, concur-
rent chemotherapy consisted of intravenous cisplatin 40 mg/m2 weekly during radiotherapy.
For patients with distant metastasis, palliative chemotherapy was the commonest treatment
strategy applied using a PF regimen for 3 courses or other regimens depended on the clinical
condition. Palliative bisphosphonate and radiotherapy was also applied on bone metastasis as
needed.
Following treatment completion (either last cycle of chemotherapy or radiation), patients
were followed up routinely with treatment response assessments planned between 8 and 12
weeks after treatment. This generally combined a physical assessment, nasoendoscopy, a naso-
pharyngeal CT-scan and other imaging for other part of the body. Following an initial follow-
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up appointment, subsequent follow-up appointments were scheduled between 3 and 6 months
during the first 2 years after all treatment completion. Follow-up data for clinical outcomes
and patient survival were obtained from the medical records. Survival time is from cancer
diagnosis until death or last follow-up. In addition, telephone communication was used for
patients whose life status could not be found in the medical records. Family members of cases
was considered as a respondent if the patient was deceased. Lost to follow up was determined
when individual discontinued any cancer management or follow-up for any reason and life
status was thus determined in the last hospital visit.
Statistical analysis
We carried out statistical analysis using multivariable semiparametric Cox regression and mul-
tivariable parametric survival analysis. We estimated models both for a sample of the complete
cases (i.e., where all variables are non-missing) and further imputed for the remaining cases
with missing variables, giving a final imputed estimation sample of all cases with valid survival
times. Cox regression imposes no assumptions about the underlying hazard function and esti-
mates the mean multiplicative impact variable on the log-hazard of failure at any given time.
This gives rise to estimated hazard ratios (HRs) which, if the proportional hazards (PH)
assumption is not violated, can be interpreted as the impact of the variable on the instanta-
neous failure rate at any given time. If the PH assumption is violated, these HRs can still be
interpreted as the geometric mean of such a relationship within the sample and, further, strati-
fication for variables where such an assumption is violated can obviate any such problems. In
our base case, we stratify by stage of NPC at entry to the study and further stratify in sensitivity
analysis.
Fully parametric regression assumes an underlying baseline hazard of failure over time that
can be specified as a function of time. Such models are estimated under either the PH assump-
tion or the accelerated failure time (AFT) assumption. We estimate models for baseline haz-
ards parameterised as exponential, lognormal, loglogistic, Gompertz, Weibull, and generalised
gamma. We inform the choice of such models by comparing estimated Akaike Information
Criteria (AIC) and Bayesian Information Criteria (BIC) metrics, and by examination of exist-
ing literature. Where missing values are exhibited for certain variables, we impute values
under the assumption that these are missing at random. We further assume that right-censor-
ing of our survival times due to loss to follow-up is non-informative.
Results
We first present descriptive statistics and the Kaplan-Meier survival curves for our full sample.
During this collection period, a total of 767 patients were registered. After exclusion of eight
patients with missing or invalid survival times, we analysed a final 759 data out of 767 from the
database. Characteristics of the study subjects are displayed in Table 1. The median age of sub-
jects was 50 years. This cohort was similar in terms of age between cases under and over the
median age. The majority of cases were male, completed education as recommended by the
Indonesian government (a minimum of 9 years’ study), were married, had government insur-
ance (for civil servant, premium payer, or for the poor) or private insurance, were diagnosed
before the introduction of national universal health coverage in 2014, had a low to normal
BMI, with a good performance score, had locally advanced disease and treated firstly with che-
motherapy or a combination of chemotherapy and radiation.
Patients were observed for a median time of 14.39 months. During the follow-up period,
266 cases (35%) died. A number of cases (n = 349, 46%) were considered as loss to follow-up
and life status was drawn from the medical records. Although some patients are observed for
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up to 145 months, we truncated the Kaplan Meier curve after the final death observed (at 46
months). The median survival time was 31.08 months (Fig 1).
We present results of the univariable analyses in Table 2 for various potential prognostic
parameters. We found that age, education status, insurance type, BMI, performance status,
Table 1. Characteristics of subjects (n = 759).
Characteristics n %
Age
<50 years 388 51.1




Education (n = 649)
�9 years 257 39.6
>9 years 392 60.4




Insurance type (n = 723)
Government insurance for civil servant or premium payer or private 300 41.5
Self-financed 113 15.6
Government insurance for the poor 310 42.9
Year of diagnosis
2014–2016 318 41.9
Before 2014 441 58.1
Body mass index (n = 708)
�22.3 499 70.5
>22.3 209 29.5








Treatment strategy (n = 643)
No treatment 58 9.0
Radiation only 28 4.4
Chemotherapy only 171 26.6
CCRT 94 14.6
Sequential chemotherapy and radiation 192 29.9
Chemotherapy-CCRT 100 15.6
ECOG: Eastern Cooperative Oncology Group
CCRT: Concurrent chemotherapy and radiation
Sequential chemotherapy-radiation: chemotherapy followed by radiation or radiation followed by chemotherapy.
https://doi.org/10.1371/journal.pone.0246638.t001
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stage at entry and treatment strategy had impacted on the OS (p values< 0.01). We further
estimated an initial set of Cox regressions under the proportional hazards assumption, with
estimated HRs, significance levels of estimated coefficients, and 95% confidence intervals (CIs)
for HRs presented. Although we only stratify in this base case by stage at entry (Table 3),
results for the treatment group are robust to further stratification by all other variables
included. This analysis showed that education status, ECOG index and first treatment modal-
ity were prognostic factors for OS (p< 0.01, p< 0.05 and p< 0.01). Individuals who had
shorter education and poorer performance had a significantly reduced OS. Of note, HRs in all
cases for these parameters are point-estimated at between 0.09 and 0.11. A hazard ratio of 0.1
implies that the hazard of failure for individuals with this characteristic have a reduction in the
hazard of (1–0.1 = 90%). These results implied that, compared to no treatment, individuals
receiving a sequential chemotherapy and radiation treatment or IC-CCRT had an approxi-
mately 90% reduction in the hazard of failure. Compared to radiation-only treatment, individ-
uals receiving a combination of sequential chemotherapy and radiation had a reduced hazard
point-estimated variously between 67% and 75%. Compared to radiation-only treatment, indi-
viduals receiving IC-CCRT had a reduced hazard point-estimated variously between 59% and
Fig 1. Kaplan-Meier curve for the whole cohort. Patients were observed for a median time of 14.39 months. The median survival time for the whole
cohort was 31.08 months.
https://doi.org/10.1371/journal.pone.0246638.g001
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Table 2. Univariable analyses for prognostic factors.
Characteristics NPC cases (n = 759)
HR lower CI upper CI
Age
<50 Ref
�50 1.703 ��� 1.335 2.173
Sex
Female Ref
Male 1.068 0.817 1.397
Education
�9 years Ref
>9 years 0.473 ��� 0.362 0.618
Marital status
Single Ref
Married 1.287 0.721 2.298
Widowed 1.499 0.590 3.810
Insurance type
Civil servant/premium payer/private Ref
Self-financed 0.996 0.662 1.500
Government insurance for the poor 1.688 ��� 1.296 2.199
Year of diagnosis
2014–2016 Ref
Before 2014 0.951 0.746 1.212
Body mass index
�22.3 Ref
>22.3 0.605 ��� 0.453 0.808
ECOG performance index
0–1 Ref
2 2.044 ��� 1.497 2.792
3 4.668 ��� 2.277 9.571
Stage at diagnosis
I-II Ref
III-IVB 2.750 ��� 1.410 5.364
IVC 4.694 ��� 2.299 9.584
Treatment strategy
No treatment Ref
Radiation only 0.214 ��� 0.120 0.383
Chemotherapy only 0.262 ��� 0.183 0.377
CCRT 0.073 ��� 0.045 0.120
Sequential chemotherapy and radiation 0.090 ��� 0.061 0.131
Chemotherapy-CCRT 0.100 ��� 0.065 0.155
HR: hazard ratio
CCRT: concurrent chemotherapy and radiation
��� p< 0.01.
https://doi.org/10.1371/journal.pone.0246638.t002
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77%. In addition, compared to radiation only and chemotherapy only, combination of chemo-
therapy and radiation either in CCRT, sequential scheme, or IC-CCRT had an association
with better survival estimation (HR = 0.226, 95%CI 0.089–0.363, p = 0.001 and HR = 0.390,
95% CI 0.260–0.519, p< 0.01, respectively) (Table 4).
Table 3. Multivariable analyses using Cox regression (stratified by stage at diagnosis).
Complete cases, n = 399 Multiple imputation, n = 759
HR lower CI upper CI HR lower CI upper CI
Age
<50 1 (ref)
�50 1.352 # 0.970 1.884 1.259 # 0.967 1.638
Sex
Female 1 (ref)
Male 1.130 0.788 1.622 0.936 0.707 1.239
Education status
�9 years 1(ref)
>9 years 0.693 # 0.475 1.010 0.576 ��� 0.418 0.795
Marital status
Single 1 (ref)
Married 2.269 0.818 6.296 1.691 # 0.900 3.178
Widowed 2.296 0.581 9.073 1.682 0.624 4.534
Insurance type
Civil servant/premium payer 1 (ref)
Self-financed 1.013 0.494 2.077 1.013 0.624 1.643
Insurance for the poor 0.935 0.630 1.388 0.938 0.667 1.318
Year of diagnosis
2014–2016 1 (ref)
Before 2014 1.305 0.906 1.880 1.040 0.766 1.411
Body mass index
�22.3 1 (ref)
>22.3 0.776 0.536 1.125 0.795 # 0.581 1.087
ECOG performance
0–1 1 (ref)
2 1.523 �� 1.076 2.156 1.438 �� 1.042 1.984
3 2.607 �� 1.180 5.761 1.703 0.719 4.037
Treatment strategy
No treatment 1 (ref)
Radiation only 0.432 �� 0.188 0.992 0.355 ��� 0.186 0.680
Chemotherapy only 0.309 ��� 0.170 0.560 0.263 ��� 0.176 0.393
CCRT 0.065 ��� 0.026 0.163 0.107 ��� 0.060 0.191
Seq. chemotherapy- radiation 0.107 ��� 0.057 0.199 0.108 ��� 0.069 0.167
Induction chemo-CCRT 0.099 ��� 0.047 0.206 0.106 ��� 0.064 0.177
CCRT: concurrent chemotherapy and radiation
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We also estimated the above models employing parametric survival analysis (Table 5). For
ease of precise interpretation of time ratios, we do not stratify our parametric analysis. We do,
however, compare coefficients obtained in stratified analysis and results are robust to stratifi-
cation. Further, the significance of staging coefficients in explaining ancillary parameters is
not rejected at any conventional level (p-values estimated between 0.678 and 0.760). When
comparing AIC and BIC metrics across our candidate baseline hazard functions, the best-per-
forming is the lognormal. Further, existing literature suggests some support for the use of a
lognormal parameterisation [40, 41]. Consequently, we estimate survival functions with this
parameterisation. As lognormal survival analysis is parameterised under the AFT assumption,
time ratios (indicating the multiplicative relationship with survival time) replace HRs in these
results. Consequently, the interpretation of these coefficients is that a time ratio above 1 indi-
cates a characteristic beneficial to survival, and a time ratio below 1 indicates a characteristic
harmful to survival. Findings showed that individuals with older age, shorter education, poorer
ECOG, and more advanced stage had a reduced OS compared to their counterparts. Individu-
als receiving treatment of any strategy had a better survival compared to individuals with no
treatment. Combination of chemotherapy and radiation either in sequential scheme, CCRT,
or IC-CCRT correlated with definitely better survival when compared to radiation-only or
chemotherapy-only treatment (TR = 3.108, 95% CI 1.274–4.942, p< 0.01 and TR = 2.531, 95%
CI 1.829–3.233, p< 0.01, respectively) (Table 4).
Fig 2a–2f demonstrated that cases with older age, shorter education, poorer ECOG status
and more advanced disease had worse OS compared to their counterparts. Cases receiving no
treatment, radiation only, and chemotherapy only also had worse survival compared to those
receiving combination of chemotherapy and radiation either in sequential scheme, CCRT, or
IC-CCRT. We also used estimates from our parametric model (as in Table 5) to estimate
extrapolated survival beyond the maximum timeframe offered by our analysis, as shown in
Fig 3. We estimated the OS at 5 years to be around 35%.
Discussion
Summary of key findings
This study presents the first comprehensive and most extensive report on the survival of NPC
patients for Indonesian cases. Despite being an endemic region, data on survival of NPC cases
in Indonesia has been underreported to date. In this cohort, patients’ median OS of 31 months
was relatively low compared to other reports from both endemic and non-endemic areas.
Table 4. Treatment combination comparison.
Analysis Treatment combination comparison
Hazard ratio Lower CI Upper CI
Semi-parametric regression CCRT+sequential chemo-radiation+chemo-CCRT vs radiation only 0.226 ��� 0.089 0.363
CCRT+sequential chemo-radiation+ chemo-CCRT vs chemotherapy only 0.390 ��� 0.260 0.519
Time ratio Lower CI Upper CI
Parametric regression CCRT+sequential chemo-radiation+chemo-CCRT vs radiation only 3.108 ��� 1.274 4.942
CCRT+sequential chemo-radiation+chemo-CCRT vs chemotherapy only 2.531 ��� 1.829 3.233
CCRT: concurrent chemotherapy-radiation
HR: hazard ratio (for semi-parametric analyses)
TR: time ratio (for fully parametric analyses)
��� p< 0.01.
https://doi.org/10.1371/journal.pone.0246638.t004
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Table 5. Multivariable analyses using parametric (lognormal) regression.
Complete cases, n = 399 Multiple imputation, n = 759
TR lower CI upper CI TR lower CI upper CI
Age
<50 1 (ref)
�50 0.810 0.622 1.054 0.740 �� 0.584 0.937
Sex
Female 1 (ref)
Male 0.900 0.681 1.190 1.067 0.832 1.368
Education status
�9 years 1 (ref)
>9 years 1.368 �� 1.027 1.822 1.564 ��� 1.185 2.064
Marital status
Single 1 (ref)
Married 0.559 0.279 1.118 0.601 # 0.359 1.005
Widowed 0.604 0.220 1.662 0.626 0.259 1.512
Insurance type
Civil servant/premium 1 (ref)
Self-financed 0.833 0.489 1.419 0.933 0.614 1.419
Insurance for the poor 0.960 0.705 1.309 0.961 0.710 1.301
Year of diagnosis
2014–2016 1 (ref)
Before 2014 1.007 0.746 1.358 1.119 0.852 1.470
Body mass index
�22.3 1 (ref)
>22.3 1.116 0.839 1.484 1.143 0.875 1.492
ECOG performance
0–1 1 (ref)
2 0.704 �� 0.530 0.935 0.710 �� 0.535 0.942
3 0.446 �� 0.216 0.924 0.621 0.302 1.279
Stage
I-II 1 (ref)
III-IVB 0.374 ��� 0.191 0.731 0.381 ��� 0.218 0.667
IVC 0.298 ��� 0.142 0.624 0.355 ��� 0.189 0.668
Treatment strategy
No treatment 1 (ref)
Radiation only 2.484 �� 1.155 5.343 3.107 ��� 1.621 5.958
Chemotherapy only 2.519 ��� 1.468 4.323 3.492 ��� 2.347 5.195
CCRT 8.439 ��� 4.191 16.99 6.931 ��� 4.235 11.343
Seq. chemo-radiation 6.777 ��� 3.940 11.659 8.739 ��� 5.774 13.227
Induction chemo-CCRT 6.738 ��� 3.617 12.553 8.790 ��� 5.527 13.981
CCRT: concurrent chemotherapy-radiation
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Fig 2. Overall survival by multiple variables. Individuals with older age (2a), shorter education (2b), poorer ECOG status (2c)
and more advanced disease at entry (2d) had worse overall survival when compared to their counterparts. Individuals receiving no
treatment, radiation only and chemotherapy only also had worse overall survival when compared to those receiving combination
of chemotherapy and radiation either in sequential scheme, CCRT, or IC-CCRT (2e). Individuals receiving no treatment,
radiation only and chemotherapy only definitely had worse overall survival when compared to those receiving combination of
chemotherapy and radiation all together (2f).
https://doi.org/10.1371/journal.pone.0246638.g002
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When extrapolated to 5-year survival time, the OS rate presented in this data only reached
35%. There were significant survival differences between cases with younger age, longer dura-
tion of education, better ECOG performance status, earlier clinical stage, and those receiving
combination of chemotherapy and radiation, and their counterparts.
Comparison with other studies in endemic and non-endemic areas
Low survival status of patients with NPC has been previously been reported from Indonesia.
An earlier study by the team reported a 21-month median survival from 78 selected cases diag-
nosed from 2008–2011 which had a shorter follow-up time due to focusing on factors influenc-
ing the duration of radiation waiting lists [42]. Data from these cases were also included in the
larger dataset reported in this manuscript. A further study in Indonesia demonstrated a 2-year
OS of 39–71% in young, non-metastatic cases [37]. Combining this study with earlier reports,
survival of Indonesian NPC patients is lower than those reported from surrounding endemic
Asian countries which ranged from 54.7%-83.2 [12, 16, 19, 21, 43–45], and from non-endemic
areas (ranging from 49.7%-69.1) for 5-year OS [17, 20, 46]. Studies that recruited only cases
Fig 3. Actual and predicted (and extrapolated) survival. Estimates from parametric model (as shown in Table 5) was used to estimate extrapolated
survival beyond the maximum timeframe offered by our analysis. The estimated 5-year overall survival is around 35%.
https://doi.org/10.1371/journal.pone.0246638.g003
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with early disease demonstrated much better survival (94.5%-96.5%) [47, 48]. The predicted
rate for 5-year survival for our present cohort (35%) matched only the survival rate of patients
in the US four decades ago, between 1973–1979 [21].
Prognostic factors and clinical and population health applicability
Prognostic factors favourable to survival in the present study included young age,
education > 9 years, a good performance index, early stage of disease and undergoing a com-
bination of chemotherapy and radiation treatment. Some studies reported various cut-off val-
ues (40–55 years) for univariable analyses regarding age [18–21, 28]. Our findings are
consistent demonstrating a survival benefit in young age. Education has generally drawn atten-
tion as a crucial factor with worse survival in the lower educational groups [16, 49]. Large epi-
demiological studies have highlighted socioeconomic differences in cancer survival that are
more pronounced than those in cancer incidence, with lower survival for individuals in disad-
vantaged socioeconomic conditions [50, 51]. However, teasing apart the causal argument from
selection persists in making it difficult to determine the underlying mechanisms influencing
this trend. The Indonesian government made it obligatory for an education duration of 9 years
since 1994, 13 years prior to the intake of NPC cases in our current panel, but lower educa-
tional attainment persists. Alongside identifying and addressing barriers to completing mini-
mum education years, there may be scope to explore health promotion approaches to
encourage healthy lifestyles particularly in rural areas where education levels are reduced (see
S1 Table).
Aligned with previous findings, performance index and nutritional status that was deter-
mined by BMI were found to be closely associated with stage of disease at presentation (see S2
Table), with both generally being low in the presence of advanced disease [31]. Tumour site
and stage may directly impair the oral intake of patients with cancer in the head and neck area
and a low performance status may enlarge the risk of nutritional worsening [52]. Bozetti et al
also confirmed an association of primary site and ECOG status with nutritional risk score [53].
However, nutritional status of our patients did not have a significant impact on their survival
status.
The late presentation of NPC in the local setting of Yogyakarta needs to be addressed. At
both the health service and patient level, known barriers to earlier presentation exist. At the
health service level, a poor diagnosis by general practitioners in the local primary health cen-
tres has previously been found to lead to a delay of patient referral [54]. Similarly, findings in
Malaysia highlighted the low knowledge and awareness of NPC by health professionals may
have an impact on delayed diagnosis [55] and patient outcomes [56]. For patients, low aware-
ness may be linked to lack of visibility of the nasopharyngeal region, so tumour development
may not be evident initially. Additionally, NPC-associated symptoms often mimic manifesta-
tion of other chronic diseases in head and neck area, such as chronic rhinitis, hearing impair-
ments and headache [36]. Denial of illness and economic constraints may become further
factors influencing delayed diagnosis and treatment [57]. Once identified, national universal
health coverage ensures access to necessary treatments for NPC patients in Indonesia follow-
ing diagnosis. This study highlights increased survival when presenting and accessing such
treatments at an earlier stage of NPC. Wider benefits to patients of increased access to medical
treatments through national universal health coverage are starting to be identified [58]. How-
ever, efforts to increase early presentation must be met by simultaneous efforts to reduce con-
voluted referral processes that may produce long waiting times between presentation and
diagnosis.
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Treatment strategy was found to have an impact on the survival status in NPC cases in this
study. This aligns with findings from previous literature. When appropriate to the stage and in
the absence of problematic comorbidity, various treatment strategy for NPC can provide good
clinical outcomes and favourable survival [12, 34, 59]. For all stage I NPC without very bulky
tumours, receipt of radiation alone is recommended with best option using IMRT [10, 34].
The addition of platinum-based chemotherapy improves clinical outcomes in physically fit
patients with stage II-IVB either in the form of IC-CCRT,CCRT-AC, or CCRT alone [14, 16,
34, 59–62]. Sequential chemotherapy and radiation can be another strategy, especially in stage
II NPC [11]. In our local panel, patients received radiation from 2D and 3D machines except
those treated from early 2017 when IMRT was firstly introduced. There was variation in clini-
cal outcome and the best result was achieved through CCRT and CCRT-AC approaches.
Sequential chemo-radiation was widely applied especially before 2014. This strategy often
became an option considering the long waiting lists for radiation treatment as shown by two
previous studies from our local cases [42, 63]. and to accommodate a lower toxicity in patients
with low performance status. The findings of the study suggest that an optimal strategy for
NPC patients is a combination of radiotherapy and chemotherapy in locally advanced patients.
Combination can be in a form of CCRT and CCRT-AC, although sequential treatment could
be considered for those with low ECOG and old age. Whilst recommendations of treatment
strategies for NPC in Indonesia can be guided by this study, they need to account for a context
with limited equipment for delivering radiation therapies and complex referral systems.
All prognostic parameters obtained from this study may serve as targets for improvement.
While the Indonesian government pursues efforts to provide optimal equipment in all oncol-
ogy centres, optimization and refinement of the existing health service delivery could be effec-
tive to give NPC patients better access to optimal treatments and which may positively
influence survival. A key area to direct investment will be in radiotherapy equipment which is
necessary to support increases in capacity to deliver optimal treatments for NPC, alongside
support wider capacity in supporting treatment delivery for other cancer types.
Strength and study limitation
A strength of this study is the inclusion of statistical analyses using fully parametric tests, sup-
porting the first comprehensive report on Indonesian NPC survival. This also contributes to
gaps in literature about NPC treatment in low- and middle-income countries. The study also
has limitations. Our study design is retrospective, where it relies greatly on the availability of
data from existing medical records, and may be subject to caveats when using routine data,
such as potential coding errors by those creating and maintaining clinical records. A further
limitation is the high number of patients lost to follow up in the life status (46%) which may
introduce bias in the calculation of survival duration.
Conclusion
This study provides a comprehensive report on the survival of NPC patients for Indonesian
cases. Median OS for the cohort was low compared to those reported across international liter-
ature in both endemic and non-endemic regions. These findings highlight the need to develop
strategies to improve the delivery of care and management of patients with NPC in areas such
as Yogyakarta in Indonesia. Age, education, ECOG status, clinical stage and treatment strategy
were independent predictors for the patients’ OS and may serve as targets for future improve-
ment initiatives.
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